Elixinol Global Stock Number Of Shares Shorted
| ELLXF Stock | USD 0.03 0.02 700.00% |
Elixinol Global fundamentals help investors to digest information that contributes to Elixinol Global's financial success or failures. It also enables traders to predict the movement of Elixinol Pink Sheet. The fundamental analysis module provides a way to measure Elixinol Global's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elixinol Global pink sheet.
Elixinol |
Elixinol Global Company Number Of Shares Shorted Analysis
Elixinol Global's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Elixinol Global has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The number of shares shorted for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Elixinol Fundamentals
| Return On Equity | -0.71 | |||
| Return On Asset | -0.33 | |||
| Profit Margin | (1.72) % | |||
| Operating Margin | (1.63) % | |||
| Current Valuation | 2.06 M | |||
| Shares Outstanding | 316.27 M | |||
| Shares Owned By Insiders | 15.67 % | |||
| Shares Owned By Institutions | 4.83 % | |||
| Price To Book | 0.72 X | |||
| Price To Sales | 0.59 X | |||
| Revenue | 14.13 M | |||
| Gross Profit | 4.9 M | |||
| EBITDA | (24.15 M) | |||
| Net Income | (17.02 M) | |||
| Cash And Equivalents | 6.93 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 250 K | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 3.58 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (14.07 M) | |||
| Earnings Per Share | (0.04) X | |||
| Number Of Employees | 17 | |||
| Beta | 1.71 | |||
| Market Capitalization | 6.5 M | |||
| Total Asset | 25.33 M | |||
| Z Score | 15.0 | |||
| Net Asset | 25.33 M |
About Elixinol Global Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elixinol Global's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elixinol Global using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elixinol Global based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Elixinol Pink Sheet
Elixinol Global financial ratios help investors to determine whether Elixinol Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Elixinol with respect to the benefits of owning Elixinol Global security.